BR0012592A - Compound, use of compounds, combination, and pharmaceutical preparation for oral or parenteral use - Google Patents

Compound, use of compounds, combination, and pharmaceutical preparation for oral or parenteral use

Info

Publication number
BR0012592A
BR0012592A BR0012592-0A BR0012592A BR0012592A BR 0012592 A BR0012592 A BR 0012592A BR 0012592 A BR0012592 A BR 0012592A BR 0012592 A BR0012592 A BR 0012592A
Authority
BR
Brazil
Prior art keywords
compounds
oral
compound
combination
pharmaceutical preparation
Prior art date
Application number
BR0012592-0A
Other languages
Portuguese (pt)
Inventor
Wilhelm Amberg
Georg Kettschau
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR0012592A publication Critical patent/BR0012592A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTO, USO DOS COMPOSTOS, COMBINAçãO, E, PREPARAçãO FARMACêUTICA PARA USO ORAL OU PARENTERAL". A invenção está relacionada a compostos com a fórmula ( I ) na qual os substituintes possuem os significados citados na descrição. A invenção está relacionada ainda à utilização dos mencionados derivados."COMPOUND, USE OF COMPOUNDS, COMBINATION, AND PHARMACEUTICAL PREPARATION FOR ORAL OR PARENTERAL USE". The invention relates to compounds of formula (I) wherein the substituents have the meanings cited in the description. The invention further relates to the use of said derivatives.

BR0012592-0A 1999-07-20 2000-07-05 Compound, use of compounds, combination, and pharmaceutical preparation for oral or parenteral use BR0012592A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19933164A DE19933164A1 (en) 1999-07-20 1999-07-20 New carboxylic acid derivatives with 5,6 substituted pyrimidine ring, their production and use as endothelin receptor antagonists
PCT/EP2000/006293 WO2001005771A1 (en) 1999-07-20 2000-07-05 Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
BR0012592A true BR0012592A (en) 2002-05-28

Family

ID=7914884

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012592-0A BR0012592A (en) 1999-07-20 2000-07-05 Compound, use of compounds, combination, and pharmaceutical preparation for oral or parenteral use

Country Status (21)

Country Link
EP (1) EP1196394A1 (en)
JP (1) JP2003505377A (en)
KR (1) KR20020019550A (en)
CN (1) CN1367778A (en)
AR (1) AR030026A1 (en)
AU (1) AU6561500A (en)
BG (1) BG106321A (en)
BR (1) BR0012592A (en)
CA (1) CA2379545A1 (en)
CZ (1) CZ2002190A3 (en)
DE (1) DE19933164A1 (en)
HU (1) HUP0202646A3 (en)
IL (1) IL147666A0 (en)
MX (1) MXPA02000616A (en)
NO (1) NO20020254L (en)
PL (1) PL353165A1 (en)
SK (1) SK772002A3 (en)
TR (1) TR200200622T2 (en)
TW (1) TW555749B (en)
WO (1) WO2001005771A1 (en)
ZA (1) ZA200200333B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2712865B1 (en) * 2009-07-10 2016-03-16 Cadila Healthcare Limited Improved process for the preparation of ambrisentan
EP2547663A1 (en) 2010-03-15 2013-01-23 Natco Pharma Limited A process for the preparation of highly pure ambrisentan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (en) * 1996-09-05 1998-03-12 Basf Ag New carboxylic acid derivatives, their production and use as mixed ET¶A¶ / ET¶B¶ receptor antagonists
NZ504316A (en) * 1997-10-31 2002-12-20 Basf Ag Pyrimidine substituted carboxylic acid derivatives which have amido side-chains useful as endothelin receptor antagonists

Also Published As

Publication number Publication date
TW555749B (en) 2003-10-01
JP2003505377A (en) 2003-02-12
ZA200200333B (en) 2003-04-30
IL147666A0 (en) 2002-08-14
DE19933164A1 (en) 2001-01-25
CZ2002190A3 (en) 2003-08-13
NO20020254L (en) 2002-02-20
BG106321A (en) 2002-08-30
EP1196394A1 (en) 2002-04-17
AU6561500A (en) 2001-02-05
HUP0202646A3 (en) 2003-03-28
NO20020254D0 (en) 2002-01-17
PL353165A1 (en) 2003-10-20
KR20020019550A (en) 2002-03-12
AR030026A1 (en) 2003-08-13
CA2379545A1 (en) 2001-01-25
HUP0202646A2 (en) 2003-02-28
MXPA02000616A (en) 2002-08-30
CN1367778A (en) 2002-09-04
SK772002A3 (en) 2003-01-09
TR200200622T2 (en) 2002-06-21
WO2001005771A1 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
BRPI0215312B8 (en) compound, use of a compound, pharmaceutical composition, and process for preparing a compound
BR0007174A (en) Compound, pharmaceutical preparation and use of compounds
PT1140993E (en) GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
ATE297203T1 (en) ANTITHRBOTIC AGENTS
BR9713147A (en) Benzamidoaldehyde, use of it, benzamide, and drug preparation for oral, parenteral or intraperitoneal administration.
DE60032780D1 (en) Tetrahydroquinoline DERIVATIVES
PT1413582E (en) PYRROLOBENZODIAZEPINAS DIMERICAS
BR0007504A (en) Triazole compound, drug, and use of at least one compound
ATE306261T1 (en) ANTITHROMBOTIC AGENTS
BR0109703A (en) Piperazine Derivatives
BR9913592A (en) Compounds, compound preparation process, and pharmaceutical compositions
BRPI0414539A (en) compound, pharmaceutical composition, and use of a compound
BR0212386A (en) Compound, pharmaceutical formulation, and use of a compound
BR9712816A (en) Benzamidine derivatives and their use as drugs with an ltb4 antagonistic activity
PT1009436E (en) DERIVED FROM ACRIDINE TO INCREASE THE ORAL TAXOL BIODISPONIBILITY
BR9909739A (en) Benzothiadiazoles and derivatives
BR0100691A (en) Cosmetic or dermatological preparation, and, use thereof
BR0012475A (en) Titanium compounds, preparation and use thereof
BR0114380A (en) 1-Aminobutan-3-ol-substituted derivatives
BR9814951A (en) Carboxylic acid derivative, use of it, preparation of medication for oral, parenteral use, combination, use of compounds, structural fragment, use of it, endothelin receptor antagonist, and, compound
BR9814495A (en) Compound, process to prepare it, use of it, pharmaceutical composition, and, process
SE9504662D0 (en) New compounds
UY26144A1 (en) NEW CRYSTALLINE FORMS OF AN ANTIBIOTIC MACROLID.
BR0012592A (en) Compound, use of compounds, combination, and pharmaceutical preparation for oral or parenteral use
FI852743A0 (en) ACETYLENISKA FENOXIPROPANOLDERIVAT OCH PHARMACEUTICAL COMPOSITION FOER BEHANDLING AV HYPERTONI.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1927 DE 11/12/2007.